793 related articles for article (PubMed ID: 12116021)
1. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART.
O'Sullivan CE; Peng R; Cole KS; Montelaro RC; Sturgeon T; Jenson HB; Ling PD
J Med Virol; 2002 Jul; 67(3):320-6. PubMed ID: 12116021
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.
Petrara MR; Cattelan AM; Zanchetta M; Sasset L; Freguja R; Gianesin K; Cecchetto MG; Carmona F; De Rossi A
J Clin Virol; 2012 Mar; 53(3):195-200. PubMed ID: 22209290
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents.
Bekker V; Scherpbier H; Beld M; Piriou E; van Breda A; Lange J; van Leth F; Jurriaans S; Alders S; Wertheim-van Dillen P; van Baarle D; Kuijpers T
J Infect Dis; 2006 Nov; 194(9):1323-30. PubMed ID: 17041860
[TBL] [Abstract][Full Text] [Related]
4. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
Piriou ER; van Dort K; Nanlohy NM; van Oers MH; Miedema F; van Baarle D
Eur J Immunol; 2005 Mar; 35(3):796-805. PubMed ID: 15724243
[TBL] [Abstract][Full Text] [Related]
5. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
[TBL] [Abstract][Full Text] [Related]
6. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection.
Bauer CC; Aberle SW; Popow-Kraupp T; Kapitan M; Hofmann H; Puchhammer-Stöckl E
J Med Virol; 2005 Jan; 75(1):54-8. PubMed ID: 15543583
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
8. High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology.
Stevens SJ; Blank BS; Smits PH; Meenhorst PL; Middeldorp JM
AIDS; 2002 May; 16(7):993-1001. PubMed ID: 11953465
[TBL] [Abstract][Full Text] [Related]
9. Quantitative PCR in EBV-infected renal transplant patients.
Merlino C; Cavallo R; Bergallo M; Giorgi S; Forgnone F; Re D; Sinesi F; Musso T; Negro Ponzi A
New Microbiol; 2001 Jul; 24(3):223-9. PubMed ID: 11497078
[TBL] [Abstract][Full Text] [Related]
10. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma.
Bonnet F; Jouvencel AC; Parrens M; Leon MJ; Cotto E; Garrigue I; Morlat P; Beylot J; Fleury H; Lafon ME
J Clin Virol; 2006 Aug; 36(4):258-63. PubMed ID: 16762591
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus and human papillomavirus infections and oropharyngeal squamous cell carcinomas.
Szkaradkiewicz A; Kruk-Zagajewska A; Wal M; Jopek A; Wierzbicka M; Kuch A
Clin Exp Med; 2002 Nov; 2(3):137-41. PubMed ID: 12447611
[TBL] [Abstract][Full Text] [Related]
12. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis.
Blaschke S; Schwarz G; Moneke D; Binder L; Müller G; Reuss-Borst M
J Rheumatol; 2000 Apr; 27(4):866-73. PubMed ID: 10782808
[TBL] [Abstract][Full Text] [Related]
14. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR.
Dehee A; Asselot C; Piolot T; Jacomet C; Rozenbaum W; Vidaud M; Garbarg-Chenon A; Nicolas JC
J Med Virol; 2001 Nov; 65(3):543-52. PubMed ID: 11596092
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus in pediatric patients after renal transplantation.
Schwab M; Böswald M; Korn K; Ruder H
Clin Nephrol; 2000 Feb; 53(2):132-9. PubMed ID: 10711415
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease.
Verschuuren E; van der Bij W; de Boer W; Timens W; Middeldorp J; The TH
J Med Virol; 2003 Feb; 69(2):258-66. PubMed ID: 12683416
[TBL] [Abstract][Full Text] [Related]
18. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial.
de Lastours V; LeGoff J; Brière J; Agbalika F; Boulet T; Lévy Y; Simon F; Aboulker JP; Molina JM
HIV Med; 2014 Jan; 15(1):23-9. PubMed ID: 24007426
[TBL] [Abstract][Full Text] [Related]
19. [Variability in Epstein-Barr virus serological markers in adult kidney transplant recipients].
Lauzurica R; Frías C; Bayés B; Ausina V; Romero R
Nefrologia; 2005; 25(2):185-90. PubMed ID: 15912656
[TBL] [Abstract][Full Text] [Related]
20. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy.
Simonelli C; Tedeschi R; Gloghini A; Bortolin MT; Spina M; Bidoli E; Cinelli R; De Paoli P; Carbone A; Tirelli U
Clin Infect Dis; 2005 Apr; 40(7):1022-7. PubMed ID: 15824995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
